Oropharyngeal Cancer - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 144 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oropharyngeal Cancer - Pipeline Review, H2 2016, provides an overview of the Oropharyngeal Cancer (Oncology) pipeline landscape.

Oropharyngeal cancer is a disease which malignant cells form in the tissue of oropharynx. Oropharynx is a middle part of the throat which includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types, HPV-positive, which are related to human papillomavirus infection, and HPV-negative cancers, which are usually linked to alcohol or tobacco use.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oropharyngeal Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oropharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oropharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.Oropharyngeal Cancer.

Oropharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Oropharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Oropharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Oropharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Oropharyngeal Cancer (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Oropharyngeal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Oropharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6

Introduction 7
Global Markets Direct Report Coverage 7
Oropharyngeal Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Oropharyngeal Cancer - Overview 9
Pipeline Products for Oropharyngeal Cancer - Comparative Analysis 10
Oropharyngeal Cancer - Therapeutics under Development by Companies 11
Oropharyngeal Cancer - Therapeutics under Investigation by Universities/Institutes 12
Oropharyngeal Cancer - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Oropharyngeal Cancer - Products under Development by Companies 16
Oropharyngeal Cancer - Products under Investigation by Universities/Institutes 17
Oropharyngeal Cancer - Companies Involved in Therapeutics Development 18
Advaxis, Inc. 18
AstraZeneca Plc 19
Cell Medica Limited 20
Genticel S.A. 21
Immunovaccine Inc 22
ISA Pharmaceuticals B.V. 23
Kolltan Pharmaceuticals, Inc. 24
Merck & Co., Inc. 25
Novartis AG 26
PNP Therapeutics, Inc. 27
Tessa Therapeutics Pte Ltd 28
VLPbio 29
Oropharyngeal Cancer - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
alpelisib - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
axalimogene filolisbac - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
CMD-004 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
DPXE-7 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
ganetespib - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
gedeptin - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
GTL-001 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
HNVax - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
ISA-101 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
KTN-3379 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
nimotuzumab - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
olaparib - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
pembrolizumab - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
PGV-001 - Drug Profile 135
Product Description 135
Mechanism Of Action 135
R&D Progress 135
TT-12 - Drug Profile 136
Product Description 136
Mechanism Of Action 136
R&D Progress 136
Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile 137
Product Description 137
Mechanism Of Action 137
R&D Progress 137
Oropharyngeal Cancer - Dormant Projects 138
Oropharyngeal Cancer - Product Development Milestones 139
Featured News & Press Releases 139
Aug 11, 2016: Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage 139
Apr 18, 2016: Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL Highlights Potential of the Company's Lm Technology™ Platform 139
Sep 14, 2015: FDA Awards Grant for Phase 2 Study of Axalimogene Filolisbac in HPV-Associated Head and Neck Cancer 141
Jun 09, 2015: U.S. FDA approves IND application for TT12 HP-VST to begin Phase I trial involving Adoptive T cell therapy on Oropharyngeal Cancer and Cervical Cancer 142

Appendix 143
Methodology 143
Coverage 143
Secondary Research 143
Primary Research 143
Expert Panel Validation 143
Contact Us 143
Disclaimer 144

List of Tables

Number of Products under Development for Oropharyngeal Cancer, H2 2016 9
Number of Products under Development for Oropharyngeal Cancer - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Oropharyngeal Cancer - Pipeline by Advaxis, Inc., H2 2016 18
Oropharyngeal Cancer - Pipeline by AstraZeneca Plc, H2 2016 19
Oropharyngeal Cancer - Pipeline by Cell Medica Limited, H2 2016 20
Oropharyngeal Cancer - Pipeline by Genticel S.A., H2 2016 21
Oropharyngeal Cancer - Pipeline by Immunovaccine Inc, H2 2016 22
Oropharyngeal Cancer - Pipeline by ISA Pharmaceuticals B.V., H2 2016 23
Oropharyngeal Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 24
Oropharyngeal Cancer - Pipeline by Merck & Co., Inc., H2 2016 25
Oropharyngeal Cancer - Pipeline by Novartis AG, H2 2016 26
Oropharyngeal Cancer - Pipeline by PNP Therapeutics, Inc., H2 2016 27
Oropharyngeal Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016 28
Oropharyngeal Cancer - Pipeline by VLPbio, H2 2016 29
Assessment by Monotherapy Products, H2 2016 30
Number of Products by Stage and Target, H2 2016 32
Number of Products by Stage and Mechanism of Action, H2 2016 34
Number of Products by Stage and Route of Administration, H2 2016 36
Number of Products by Stage and Molecule Type, H2 2016 38
Oropharyngeal Cancer - Dormant Projects, H2 2016 138